Last reviewed · How we verify
Tucatinib plus Trastuzumab Subcutaneous (SC) (tucatinib-plus-trastuzumab-subcutaneous-sc)
Tucatinib plus Trastuzumab SC targets HER2-positive breast cancer cells, inhibiting HER2 signaling and promoting antibody-dependent cell-mediated cytotoxicity.
At a glance
| Generic name | tucatinib-plus-trastuzumab-subcutaneous-sc |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Mechanism of action
This combination therapy works by using tucatinib to block the HER2 protein, which is overexpressed in some breast cancers, while trastuzumab binds to HER2 on the surface of cancer cells, marking them for destruction by the immune system.
Approved indications
Common side effects
Key clinical trials
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (PHASE2)
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (PHASE3)
- Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (PHASE2)
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer (PHASE2)
- A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: